About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

NCT00308737·176 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Mannkind Corporation

Age

18–70

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

For All Subjects:
* Nonsmoking
* Body mass index \<42 kg/m2
* FEV1 greater than or equal to 70% of predicted , DLco and TLC greater than or equal to 80% of predicted at screening,
* No abnormalities in screening pulmonary radiology
For Subjects with diabetes mellitus:
* Type 1 or type 2 diabetes for at least 2 years
* HbA1c greater than or equal to 6.6 % and less than or equal to 12.0 %
For Subjects without abnormalities in glucose control:
* No history of diabetes
* Normal results from a formal glucose tolerance test

You may not be if

History of chronic obstructive pulmonary disease, asthma, or other significant pulmonary disease
Significant renal, hepatic, or cardiac disease
Women who are pregnant, lactating, or planning on becoming pregnant
Subjects who have participated in studies of other investigational drugs within the previous 3 months
Evidence of severe complications of diabetes

The record

StatusCompleted

PhasePhase 3

Taking part2,053

StartedJun 2005

UpdatedOct 16, 2014

Conditions

Diabetes, Type 1 Diabetes, Type 2

Where176

Southwest Health Ltd Research Division
Phoenix, Arizona, United States
Lovelace Scientific Resources
Phoenix, Arizona, United States
Northwest Medical Center
Phoenix, Arizona, United States

Clareo Health | Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes